Get started

Signalservice

Lingrid | GOLD Weekly OUTLOOK. What to Expect This September?OANDA:XAUUSD market spent the entire week in a consolidation zone, trading back and forth. The price tested the resistance multiple times, but we did not see any higher highs or higher closes. Looking at the weekly chart, we can observe that the price action has created two doji candles in a row, suggesting that a breakout—either above or below last week's range—is imminent. I believe the market may be overextended based solely on price action, not considering fundamental factors. Since March, we have seen only bullish months, with June being neutral. Additionally, the price has formed a significant divergence on the weekly timeframe signaling the pullback. If we examine September trends over the past five years, we notice that this month has typically been bearish, despite the overall bullish trend. Given this historical context, I suspect we could see a deeper pullback toward the 50% retracement level of the previous month's range. However, it's important to note that this pullback may not happen immediately, so caution is advised in chasing the market, especially after two neutral weekly candlesticks. Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
OANDA:XAUUSDShort
by Lingrid
13
Lingrid | AUDUSD complex PULLBACK. LongFX:AUDUSD broken out of an expanding triangle pattern. The recent break and close below the support level that had been respected multiple times indicates a shift in trend. On the 1H timeframe, the market is currently pulling back towards the lower border of the channel, which presents a potential bounce point, especially since the major trend remains bullish on the D. Given this bullish context, I expect there is a good chance the market will gain momentum and push upwards. This suggests that price may enter a consolidation phase as it oscillates between support and resistance. It will be important to monitor the price action around the lower border of the channel and the support level for confirmation of the expected movement. My goal is the resistance zone at 0.67613 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Long
by Lingrid
5
Lingrid | SOLUSDT breakout-PULLBACK-Continuation tradeThe price perfectly fulfilled my previous idea. It hit the target level. BINANCE:SOLUSDT has been ranging between the 140 and 160 levels, but it has recently broken and closed below this range. This indicates a shift in market dynamics. I believe the market is now heading to retest the area where we observed a bullish impulse leg previously. The break below the upward trendline suggests that the price has entered a consolidating phase, which was signaled by the price being above the trendline and showing bullish momentum. Given this context, I expect the market to push a little further down towards a key round number, which could act as a psychological level of support. My target is support level at 120 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
3
DXY- Where to?After forming a double top above the 106 level, with the second top occurring at the beginning of July, the DXY (US Dollar Index) began to decline. After breaking the 104 neckline of this pattern, the index tumbled to the key support level at 100.50, which coincides with the price level from the start of the year. As expected, the price started to recover, and at the time of writing, it is trading at 101.66. Although there has been a rebound from support, it's too early to consider the trend reversed. For a confirmed reversal, the price needs to break back above the 102.50 zone. If this happens, the price could continue upward, with a longer-term target around the 106 level and an interim resistance at 104. Conversely, if the index fails to break above 102.50 and drops back to 100.50, there is a high probability of a further decline, with 98 as the next target.
TVC:DXY
by Mihai_Iacob
EURUSD Buy from the confluence zoneEURUSD closed bullish on the monthly timeframe but faced resistance and pulled back from that zone. The price is now retracing toward the psychological level at 1.1000, which acts as a key support area. On the daily chart, the market remains in a bullish trend, suggesting that this pullback could offer a chance for a rebound. The market may bounce off a confluence zone created by the lower channel boundary, a trendline, and the psychological level at 1.1000. This combination of support factors could provide a strong base for the market to continue its upward momentum. The target is the resistance zone at 1.11350
Long
by RTED_Investing
Trading minute impulseOn the minute timeframe of XAUUSD at the moment we have the completion of the impulse formation. If the price continues to move in the direction of the impulse and the support zones do not allow it to overcome the base of the impulse, it may reach the targets 1 and 2. If the price fails to advance in the direction of the momentum and overcomes the support zone at the base of the momentum, it is very likely that the price will move sideways or against the direction of the momentum.
FXOPEN:XAUUSDShort
by syomking76418
2
Gold- Drop to 2480 before reversal?In my Friday analysis, I mentioned that a break above 2530 could trigger an upward acceleration, especially since gold had been trading within a tight range throughout the week. However, this breakout did not occur. Instead, XAU/USD ended the week just above the key 2500 level. As of this writing, the price is slightly below 2500, currently at 2496, and it may continue to decline. However, there's strong support at 2480, a level that has previously acted as resistance three times—in mid-July, early August, and mid-August. If the price reaches this level, I anticipate a reversal. In conclusion, I'm looking to buy on dips, targeting a reversal that would push the price back above 2500.
OANDA:XAUUSDLong
by Mihai_Iacob
7
Final fall? Bitcion Review #BTCAfter the last fall, you entered the zone of interest. Now, we are likely to go to the white box, from which we will see the final movement down and the subsequent impulse with the renewal of new tops or without dipping into the zone of 54-56k. I look at the market extremely positively. -Because everything is down right now - Altcoins -We've held the Bitcoin level. -In a few days, it's September. -Markets rise on fear. Best regards @Forexcryptowithjohn
Long
by Forexcryptowithjohn
Lingrid | NZDCAD short from STRONG resistance zoneThe market has reached a significant resistance level on the daily timeframe, specifically at the area where a sharp bearish move occurred two months ago. The price action is currently creating a broadening triangle pattern, which can indicate a loss of momentum and increased volatility. Considering these factors, I anticipate a pullback toward the support level, especially in light of the divergence observed in the price action. Additionally, the psychological level at 0.85000 adds weight to the potential for a retracement as we might look to take profits or reassess positions around this key area. My target is support level at 0.83700 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
1
EURUSD - correction from the Resistance zoneEURUSD is currently approaching a weekly resistance level that was last tested in December 2023. Since this resistance level previously triggered a bearish reversal, we could see a potential short-term pullback or choppy price action in this area. The price might attempt a false breakout above both the channel border and the resistance level, which could lead to a short-term correction in the market. The target is the support level around 1.10500
Short
by RTED_Investing
Lingrid | AUDCAD ranging MARKET. Potential SHORTFX:AUDCAD has been consolidating following a significant move, with price action fluctuating between established support and resistance levels. This consolidation phase has formed a slight descending channel. As the market approaches the highs from the previous week, we may witness a rebound from the channel's upper boundary and the upward trendline, suggesting a potential continuation of the current sideways trend. My target is support level at 0.91330 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Short
by Lingrid
3
TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment. Why Wall Street's bullish in this drug company ? First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity. However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders. Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases. For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients. Teva Pharmaceutical's financial performance and 2024 outlook After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million. Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents. What factors contribute to Teva Pharmaceutical's success? To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments. We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter. First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market. In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter. What factors led to the recovery of Teva's generics business? The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio. The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow. Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea. I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia. However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million. Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event. Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars. For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy. However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX). Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase. However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China. The question arises: "Are there any positives?" The short answer is yes. Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter. What is driving this sales growth? Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices. Now lets talk about Risks Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis. In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance. With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits. To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance. The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market. So TEVA Pharmaceutical is a BUY? YUP
NYSE:TEVALong
by moonypto
Lingrid | GOLD trend CONTINUATION patternThe price perfectly fulfills my last idea. It hit the target zone. OANDA:XAUUSD has formed a trend continuation pattern in the shape of an ascending triangle. This pattern indicates that buying pressure is increasing as the price continues to test the resistance zone, suggesting that a breakout could be imminent. I believe that if the price successfully breaks through this resistance level, it may continue to rally, potentially reaching the 2500 resistance zone. With high-impact news scheduled for today, there is a strong possibility that the market may be poised to push towards new all-time highs. Keep an eye on the market reactions to the news, as they may provide key insights into the strength of the breakout and overall market sentiment. My goal is resistance around 2555. Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
OANDA:XAUUSDLong
by Lingrid
3
Trading minute impulseOn the minute timeframe of XAUUSD at the moment we have the completion of the impulse formation. If the price continues to move in the direction of the impulse and the support zones do not allow it to overcome the base of the impulse, it may reach the targets 1 and 2. If the price fails to advance in the direction of the momentum and overcomes the support zone at the base of the momentum, it is very likely that the price will move sideways or against the direction of the momentum.
FXOPEN:XAUUSDLong
by syomking76418
Lingrid | EURUSD bullish TRADING OpportunityThe price has indeed fulfilled my previous target idea, reaching the anticipated level. After hitting that target, the market has pulled back, with bearish sentiment pushing the price towards the support zone. FX:EURUSD has seen a retracement from the weekly resistance zone. Currently, the market is bouncing off a support level that aligns with the 78% retracement of the previous bullish weekly price range. Given that the overall trend remains bullish, I believe the bounce from this support level increases the likelihood of the market moving higher from this area. Overall, I expect the price to climb, potentially retesting the recent resistance zone above if the price breaks through the trendline. My goal is resistance around 1.11300 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Long
by Lingrid
5
Lingrid | BONKUSDT Range-Bound Market PRICE ACTIONBINANCE:BONKUSDT is currently consolidating, oscillating between resistance and support levels. Notably, it is fluctuating around the psychological level of 0.000020, which indicates that there is accumulation occurring at this level. Overall, the market has reached the April high, and on the weekly timeframe, it has formed an inside bar pattern. This could signal the potential beginning of a bull run if the price closes above this pattern. I expect the market to continue oscillating within the consolidation zone until we see a clear breakout. Any movement beyond the established resistance or support levels will provide further insights into the market's direction. My target is resistance zone aroud 0.0000222 Traders, if you liked this idea or if you have your own opinion about it, write in the comments. I will be glad 👩‍💻
Long
by Lingrid
2